Gene: C1orf21

81563
PIG13
chromosome 1 open reading frame 21
protein-coding
1q25.3
Ensembl:ENSG00000116667 Vega:OTTHUMG00000035386 UniprotKB:Q9H246
NC_000001.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.435e-2 (AD)  6.010e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2001270chr1:184524750 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg24533904chr1:184467193C1orf21Gene body6.577e-4Alcohol use disorders26763658
cg12550731chr1:184355219C1orf216.100e-8Maternal smoking in pregnancy27040690
cg12550731chr1:184355219C1orf216.460e-8Maternal smoking in pregnancy27040690

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TUB0.94
SEPT30.929
TMOD20.928
IDS0.921
HPCAL40.917
MAP20.914
PBX10.913
CYFIP20.91
TNPO20.908
TTC7B0.908

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.598
OR4F29-0.542
CSAG1-0.458
TFPI2-0.451
SGMS2-0.44
SPINK8-0.439
SH2D1A-0.428
SNHG18-0.426
BEST3-0.418
CCR2-0.41

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of C1ORF21 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of C1ORF21 gene27153756
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of C1ORF21 mRNA21298039
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of C1ORF21 mRNA24449571
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of C1ORF21 mRNA20064835
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of C1ORF21 mRNA"20382639
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF21 mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of C1ORF21 mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of C1ORF21 mRNA26079696
D016572CyclosporineCyclosporine results in decreased expression of C1ORF21 mRNA20106945
D003907DexamethasoneDexamethasone results in increased expression of C1ORF21 mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF21 mRNA28628672
D002117CalcitriolCalcitriol results in increased expression of C1ORF21 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of C1ORF21 mRNA21592394
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF21 mRNA22079256
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF21 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF21 mRNA28628672
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of C1ORF21 mRNA28001369
D010100OxygenOxygen deficiency results in increased expression of C1ORF21 mRNA26516004
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of C1ORF21 mRNA26272509
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF21 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of C1ORF21 mRNA22079256
D015474IsotretinoinIsotretinoin results in increased expression of C1ORF21 mRNA20436886
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of C1ORF21 mRNA25895662
C017947sodium arsenitesodium arsenite affects the methylation of C1ORF21 gene28589171
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of C1ORF21 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of C1ORF21 mRNA21592394
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of C1ORF21 mRNA22298810
D014212TretinoinTretinoin results in decreased expression of C1ORF21 mRNA21934132
D014212TretinoinTretinoin results in increased expression of C1ORF21 mRNA23724009|2383079
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of C1ORF21 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of C1ORF21 mRNA23179753|2627250
C111237vorinostatvorinostat results in increased expression of C1ORF21 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  
GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal